Novartis Gene Therapies, Senior Vice President and Chief Business Officer
Lisa Deschamps is Senior Vice President & Chief Business Officer of Novartis Gene Therapies (GTx), a position she’s held since September 2019.
Lisa is responsible for strategic planning and worldwide commercialization of pipeline and in-line assets across the extensive gene therapy portfolio within Novartis GTx. This includes managing significant revenue growth targets and profitability margins world-wide.
Prior to joining Novartis GTx (AveXis at the time), Lisa was the Head of the Global Neuroscience Franchise. During her 25-year career at Novartis, Lisa has successfully brought highly specialized biologic and small molecule products from the clinic to commercialization in the areas of Cardiovascular, Respiratory, Rheumatology/Immunology and Neurology, including rare and Ultra-Rare disease areas. Throughout her tenure, Lisa has worked with and led teams across U.S, Europe, LatCan and Asia/Pac in Strategic, Functional and General Management roles.
Lisa serves on a number of executive teams within the commercial and development areas of Novartis including, the Novartis GTx Leadership Team, Novartis U.S. CLT and Country President team and the Novartis Leadership Forum. She has garnered many industry awards and honors and has a number of philanthropic interests including domestic violence and pediatric cancer.
Lisa has an MBA in General Management from NYU Stern School of Business and a BBA in marketing from IONA College, Hagan School of Business.